Endocardial ablation is a medical procedure employed to treat certain heart rhythm disorders, specifically those arising from abnormal electrical pathways within the heart. Also known as catheter ablation, this minimally invasive technique involves the use of a catheter—a thin, flexible tube—that is threaded through blood vessels to reach the heart. Once in position, the catheter delivers controlled bursts of energy, often in the form of radiofrequency or cryotherapy, to selectively destroy or modify tissue responsible for erratic electrical signals. Endocardial ablation is commonly used to address conditions such as atrial fibrillation, atrial flutter, and supraventricular tachycardia. By disrupting the abnormal pathways causing irregular heartbeats, this procedure aims to restore a normal rhythm and alleviate symptoms like palpitations, fatigue, and shortness of breath. Endocardial ablation has proven to be an effective and increasingly utilized intervention, offering patients a potential solution for managing and improving their cardiac health. As with any medical procedure, individual cases may vary, and healthcare professionals will carefully evaluate each patient's specific condition to determine the most appropriate course of treatment
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India